Pawlak S - Search Results

1

Tigecycline does not prolong corrected QT intervals in healthy subjects.

Korth-Bradley JM, McGovern PC, Salageanu J, Matschke K, Plotka A, Pawlak S. Korth-Bradley JM, et al. Among authors: pawlak s. Antimicrob Agents Chemother. 2013 Apr;57(4):1895-901. doi: 10.1128/AAC.01576-12. Epub 2013 Feb 12. Antimicrob Agents Chemother. 2013. PMID: 23403419 Free PMC article. Clinical Trial.

2

Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions.

Sun W, Klamerus KJ, Yuhas LM, Pawlak S, Plotka A, O'Gorman M, Kirkovsky L, Kosa M, Wang D. Sun W, et al. Among authors: pawlak s. Clin Pharmacol Drug Dev. 2017 Nov;6(6):614-626. doi: 10.1002/cpdd.356. Epub 2017 Apr 21. Clin Pharmacol Drug Dev. 2017. PMID: 28430398 Clinical Trial.

3

Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF-07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS-CoV-2, in Healthy Adult Participants.

Zhu T, Pawlak S, Toussi SS, Hackman F, Thompson K, Song W, Salageanu J, Winter E, Shi H, Winton J, Binks M. Zhu T, et al. Among authors: pawlak s. Clin Pharmacol Drug Dev. 2022 Dec;11(12):1382-1393. doi: 10.1002/cpdd.1174. Epub 2022 Oct 26. Clin Pharmacol Drug Dev. 2022. PMID: 36285536 Free PMC article. Clinical Trial.

4

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Domagrozumab (PF-06252616), an Antimyostatin Monoclonal Antibody, in Healthy Subjects.

Bhattacharya I, Pawlak S, Marraffino S, Christensen J, Sherlock SP, Alvey C, Morris C, Arkin S, Binks M. Bhattacharya I, et al. Among authors: pawlak s. Clin Pharmacol Drug Dev. 2018 Jun;7(5):484-497. doi: 10.1002/cpdd.386. Epub 2017 Sep 7. Clin Pharmacol Drug Dev. 2018. PMID: 28881472 Clinical Trial.

5

First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects.

Banfield C, Rudin D, Bhattacharya I, Goteti K, Li G, Hassan-Zahraee M, Brown LS, Hung KE, Pawlak S, Lepsy C. Banfield C, et al. Among authors: pawlak s. Br J Clin Pharmacol. 2020 Apr;86(4):812-824. doi: 10.1111/bcp.14187. Epub 2020 Jan 28. Br J Clin Pharmacol. 2020. PMID: 31758576 Free PMC article. Clinical Trial.

6

Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.

Hibma JE, O'Gorman M, Nepal S, Pawlak S, Ginman K, Pithavala YK. Hibma JE, et al. Among authors: pawlak s. Cancer Chemother Pharmacol. 2022 Jan;89(1):71-81. doi: 10.1007/s00280-021-04368-1. Epub 2021 Oct 26. Cancer Chemother Pharmacol. 2022. PMID: 34698901 Free PMC article. Clinical Trial.

7

The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants.

Chen J, Xu H, Pawlak S, James LP, Peltz G, Lee K, Ginman K, Bergeron M, Pithavala YK. Chen J, et al. Among authors: pawlak s. Adv Ther. 2020 Feb;37(2):745-758. doi: 10.1007/s12325-019-01198-9. Epub 2019 Dec 20. Adv Ther. 2020. PMID: 31863284 Clinical Trial.

8

Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults.

Cox DS, Van Eyck L, Pawlak S, Beckerman B, Linn C, Ginman K, Thay Cha Y, LaBadie RR, Shi H, Damle B. Cox DS, et al. Among authors: pawlak s. Br J Clin Pharmacol. 2023 Sep;89(9):2867-2876. doi: 10.1111/bcp.15788. Epub 2023 May 31. Br J Clin Pharmacol. 2023. PMID: 37184075 Free article.

9

Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.

Singh RSP, Toussi SS, Hackman F, Chan PL, Rao R, Allen R, Van Eyck L, Pawlak S, Kadar EP, Clark F, Shi H, Anderson AS, Binks M, Menon S, Nucci G, Bergman A. Singh RSP, et al. Among authors: pawlak s. Clin Pharmacol Ther. 2022 Jul;112(1):101-111. doi: 10.1002/cpt.2603. Epub 2022 May 4. Clin Pharmacol Ther. 2022. PMID: 35388471 Free PMC article. Clinical Trial.

10

Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.

Hibma JE, O'Gorman M, Nepal S, Pawlak S, Ginman K, Pithavala YK. Hibma JE, et al. Among authors: pawlak s. Cancer Chemother Pharmacol. 2022 Jun;89(6):839. doi: 10.1007/s00280-022-04421-7. Cancer Chemother Pharmacol. 2022. PMID: 35303141 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters